Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

NCT02633111 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT02633111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02633111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Observational
Overall status
Active, not recruiting
Start date
October 31, 2015
Completion date
October 31, 2026
Enrollment
501 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive, b-cell non-hodgkin lymphoma